1129 GMT - Sanofi's mixed results for its itepekimab drug candidate increase the importance of a successful outcome in a late-stage trial for another investigational drug, amlitelimab, for atopic dermatitis, Jefferies analysts say in a research note. The French drugmaker and U.S. partner Regeneron last week said itepekimab missed the primary goal of a late-stage clinical trial in former smokers with chronic obstructive pulmonary disease, but met the key objective in another study. These results likely increase investors' focus on results for an amlitelimab phase 3 study due in the second half of 2025, Jefferies says. Amlitelimab is now widely seen as the key program to help offset the loss of exclusivity for Sanofi and Regeneron's blockbuster anti-inflammatory drug in 2031 and 2032, the analysts say. Sanofi shares fall 1.7%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
June 02, 2025 07:29 ET (11:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。